187671-49-4
Chemical Structure
Tyrosinase-related Protein 2 (TRP-2) (181-188)
- CAS No.: 187671-49-4
- Formula:C58H73N9O12
- Molecular Weight:1088.25
IUPAC Name: L-valyl-L-tyrosyl-L-aspartyl-L-phenylalanyl-L-phenylalanyl-L-valyl-L-tryptophyl-L-leucine
InChIKey: HRXKEXXZGCWJFY-IAWGGNPOSA-N
SMILES: CC(C)C[C@@H](C(O)=O)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](C(C)C)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC4=CC=CC=C4)NC([C@H](CC(O)=O)NC([C@H](CC5=CC=C(O)C=C5)NC([C@H](C(C)C)N)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Tyrosinase-related Protein 2 (TRP-2) (181-188) is a peptide epitope of the TRP-2 protein that conforms to the MHC class I H2-Kb binding motif. It is the major reactive epitope within TRP-2 recognized by anti-B16 CTLs, induces TRP-2-specific CTL and CD8+ T cell responses, and mediates antibody-dependent antitumor effects against lung metastasis. Tyrosinase-related Protein 2 (TRP-2) (181-188) is used in melanoma research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tyrosinase-related Protein 2 (TRP-2) (181-188) | 98.52% | Tyrosinase-related Protein 2 (TRP-2) (181-188) is a peptide epitope of the TRP-2 protein that conforms to the MHC class I H2-Kb binding motif. It is the major reactive epitope within TRP-2 recognized by anti-B16 CTLs, induces TRP-2-specific CTL and CD8+ T cell responses, and mediates antibody-dependent antitumor effects against lung metastasis. Tyrosinase-related Protein 2 (TRP-2) (181-188) is used in melanoma research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bloom MB, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. The Journal of experimental medicine. 1997 Feb 03;185(3):453-9. [Content Brief]
- [2]. Avogadri F, et al. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PloS one. 2010 Sep 10;5(9):e12670.
- [3]. Schellack C, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine. 2006 Jun 29;24(26):5461-72.
